A Phase 2 interventional study of Docetaxel and cetuximab in Gastric Cancer Adenocarcinoma Metastatic, sponsored by US Oncology Research. Completed at 47 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing cetuximab in Stomach Neoplasms — none open to participants now, none under way, none of them phase 3. Cetuximab · Stomach Neoplasms.
Among the 17 studies testing cetuximab in Stomach Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 2, and was the 10th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →None of the 17 studies testing cetuximab in Stomach Neoplasms is open now. The open studies under Stomach Neoplasms, anywhere →
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 1
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 41 across the 17 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
Sarah Cannon Research Institute has 1 study filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing cetuximab in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.
This is a Phase II, open- label, randomized, noncomparative study. Patients will be stratified at randomization by ECOG PS. There is no intent to have equal numbers of patients for each PS (ie, 0, 1, and 2), but rather stratification will be conducted to ensure that the 2 treatment arms are well-balanced for ECOG PS.
Patients will be randomly assigned to either Arm 1 - Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours or Arm 2 - Taxotere 60 mg/m2 as an IV infusion over 1 ho ur, followed by Eloxatin 130mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes. Taxotere and Eloxatin will be given on Day 1 of each 21-day cycle; ERBITUX is given on Days 1, 8, and 15 of each cycle.
Treatment will continue until disease progression or intolerable toxicity. Patients who achieve a CR will receive an additional 2 cycles of treatment. Patients will be limited to 24 months of participation, counted from the date of the first dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: radiation plus treatment with 5-FU and leucovorin is permitted, but not required.
Exclusion Criteria:
Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
Drug: Docetaxel · Drug: oxaliplatin
Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Drug: Docetaxel · Drug: cetuximab · Drug: oxaliplatin
Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
Also known as: Taxotere (docetaxel)
ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Also known as: ERBITUX (cetuximab)
Eloxatin 130 mg/m2 IV over 2 hours
Also known as: Eloxatin (oxaliplatin)
Progression-free Survival
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Treatment will continue until disease progression or intolerable toxicity, up to 2 years
Overall Survival
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
Time frame: Treatment will continue until disease progression or intolerable toxicity
Objective Response Rate (ORR)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.
Time frame: Treatment will continue until disease progression or intolerable toxicity.
Time to Response
For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.
Time frame: Treatment will continue until disease progression or intolerable toxicity
Duration of Response
The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.
Time frame: Treatment will continue until disease progression or intolerable toxicity
| Milestone | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| Started | 75 | 75 |
| Completed | 0 | 0 |
| Not completed | 75 | 75 |
| Withdrew: Adverse event | 22 | 34 |
| Withdrew: Disease progression | 39 | 32 |
| Withdrew: Patient request | 6 | 5 |
| Withdrew: Investigator request | 5 | 3 |
| Withdrew: Other | 3 | 1 |
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| Progression-free Survival | 4.7 (3.0 to 5.6) | 5.1 (4.3 to 5.9) |
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
| months | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| Overall Survival | 8.5 (7.1 to 12.0) | 9.4 (6.7 to 10.1) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.
| percentage of participants | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| Objective Response Rate (ORR) | 26.5 (16.5 to 38.6) | 38.0 (26.8 to 50.3) |
For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.
| months | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| Time to Response | 1.3 (1.1 to 5.2) | 1.4 (1.1 to 4.0) |
The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.
| months | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| Duration of Response | 7.3 (1.5 to 23.7) | 5.6 (2.3 to 13.2) |
Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DOCOX | — | 20/68 (29.4%) | 65/68 (95.6%) |
| DOCOX+Cebuximab | — | 26/72 (36.1%) | 67/72 (93.1%) |
| Event | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| FEBRILE NEUTROPENIAInfections and infestations | 7/68 | 13/72 |
| DIARRHEAGastrointestinal disorders | 5/68 | 4/72 |
| DEHYDRATIONGastrointestinal disorders | 4/68 | 3/72 |
| ANEMIABlood and lymphatic system disorders | 3/68 | 1/72 |
| ABDOMINAL PAINGastrointestinal disorders | 2/68 | 0/72 |
| GASTROINTESTINAL BLEEDINGGastrointestinal disorders | 2/68 | 0/72 |
| INFECTIONInfections and infestations | 2/68 | 1/72 |
| ALLERGIC REACTIONImmune system disorders | 1/68 | 2/72 |
| COLITISGastrointestinal disorders | 1/68 | 2/72 |
| NEUROPATHYNervous system disorders | 0/68 | 2/72 |
| Event | DOCOX | DOCOX+Cebuximab |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 45/68 | 41/72 |
| FATIGUEGeneral disorders | 33/68 | 36/72 |
| DIARRHEAGastrointestinal disorders | 26/68 | 34/72 |
| RASH ACNEFORMSkin and subcutaneous tissue disorders | 0/68 | 32/72 |
| NAUSEAGastrointestinal disorders | 26/68 | 27/72 |
| ALOPECIASkin and subcutaneous tissue disorders | 22/68 | 17/72 |
| ANEMIABlood and lymphatic system disorders | 19/68 | 19/72 |
| NEUROPATHYNervous system disorders | 17/68 | 9/72 |
| RASHSkin and subcutaneous tissue disorders | 2/68 | 17/72 |
| NEUROPATHY PERIPHERALNervous system disorders | 12/68 | 16/72 |
ITT population
| Age, Continuous(years) | DOCOX | DOCOX+Cebuximab | Total |
|---|---|---|---|
| Mean | 60.5 ± 10.9 | 61.5 ± 11.5 | 61.0 ± 11.2 |
| Sex: Female, Male(Participants) | DOCOX | DOCOX+Cebuximab | Total |
|---|---|---|---|
| Female | 16 | 15 | 31 |
| Male | 59 | 60 | 119 |
| Race/Ethnicity, Customized(participants) | DOCOX | DOCOX+Cebuximab | Total |
|---|---|---|---|
| Caucasian | 62 | 56 | 118 |
| Black | 5 | 7 | 12 |
| Hispanic | 5 | 9 | 14 |
| Asian | 3 | 1 | 4 |
| Hawaiian | 0 | 1 | 1 |
| Other | 0 | 1 | 1 |
| Region of Enrollment(participants) | DOCOX | DOCOX+Cebuximab | Total |
|---|---|---|---|
| United States | 75 | 75 | 150 |
Plan to share: No
The record gives a start of Jul 2007, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab